K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models

NAGOYA, Japan, April 6, 2026 /PRNewswire/ -- Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), today announced an upcoming presentation of non-clinical data for K‑679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity....